Flexion Therapeutics Inc  

(Public, NASDAQ:FLXN)   Watch this stock  
Find more results for Michael Merrifield�
16.48
-0.14 (-0.84%)
Real-time:   10:02AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 16.25 - 16.53
52 week 7.56 - 29.09
Open 16.50
Vol / Avg. 24,998.00/348,508.00
Mkt cap 433.85M
P/E     -
Div/yield     -
EPS -2.51
Shares 27.07M
Beta     -
Inst. own 84%
Aug 3, 2016
Q2 2016 Flexion Therapeutics Inc Earnings Call - 4:30PM EDT - Add to calendar
Aug 3, 2016
Q2 2016 Flexion Therapeutics Inc Earnings Release - 4:00PM EDT - Add to calendar
May 12, 2016
Q1 2016 Flexion Therapeutics Inc Earnings Call
May 12, 2016
Q1 2016 Flexion Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -56.39% -33.03%
Return on average equity -69.93% -37.21%
Employees 48 -
CDP Score - -

Address

10 Mall Rd Ste 301
BURLINGTON, MA 01803-4121
United States - Map
+1-781-3057777 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Flexion Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain. The Company's portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain. The Company's lead product candidate, Zilretta (also known as FX006), is a late-stage, injectable, sustained-release, intra-articular (IA) steroid for patients with moderate to severe OA pain. The Company's other product candidates include FX007, a preclinical, small-molecule tropomyosin receptor kinase A (TrkA) receptor antagonist designed to address post-operative pain, and FX005, a sustained-release p38 mitogen-activated protein (MAP), kinase inhibitor for the treatment of end-stage OA patients. The Company has not generated any revenue.

Officers and directors

Patrick J. Mahaffy Chairman of the Board
Age: 53
Bio & Compensation  - Reuters
Michael D. Clayman M.D. President, Chief Executive Officer, Co-Founder, Director
Age: 62
Bio & Compensation  - Reuters
Neil Bodick MD, PhD Chief Medical Officer & Co-Founder
Age: 68
Bio & Compensation  - Reuters
Frederick W. Driscoll Chief Financial Officer
Age: 65
Bio & Compensation  - Reuters
Scott A. Canute Independent Director
Age: 54
Bio & Compensation  - Reuters
Samuel D. Colella Independent Director
Age: 75
Bio & Compensation  - Reuters
Heath Lukatch Ph.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Sandesh Mahatme Independent Director
Age: 51
Bio & Compensation  - Reuters
Ann Merrifield Independent Director
Age: 65
Bio & Compensation  - Reuters